News Archive

November 2017

• Press Release Nov 14, 2017

  New data reinforces clinical basis for switching to Sandoz biosimilar medicines

  Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar…
• Press Release Nov 13, 2017

  Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants

  Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
• Press Release Nov 13, 2017

  Novartis highlights its differentiated late stage pipeline at the R&D update and investor event

  RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD   AMG 334 has a…
• Press Release Nov 12, 2017

  New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure

   Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common…
• Press Release Nov 11, 2017

  Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases

  Poor patients in Punjab will have access to high-quality  medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will…
• Ad-hoc Release Nov 10, 2017

  Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness

  Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
• Press Release Nov 08, 2017

  Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer

  MONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal…
• Press Release Nov 07, 2017

  Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage

  Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1]  PsA can lead to reduced…
• Press Release Nov 06, 2017

  Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years

  For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx® have no radiographic progression of the spine at 4 years[1] These new data…
• Press Release Nov 06, 2017

  Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL

  Application follows sBLA submission to the FDA for r/r DLBCL which marked second US application for first-ever FDA approved CAR-T therapy Building on the US r/r B-cell ALL experience, Novartis…
• Press Release Nov 02, 2017

  Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program

  Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD)  Clinical trial is part of the…
• Press Release Nov 01, 2017

  Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease

  Primary results of pivotal KymriahTM Phase II JULIET study in relapsed/refractory DLBCL  Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to…